|3.||Sarcoma (Soft Tissue Sarcoma)
|1.||Singer, Samuel: 13 articles (01/2015 - 10/2002)|
|2.||Lazar, Alexander J: 8 articles (08/2015 - 03/2011)|
|3.||Lev, Dina: 8 articles (04/2015 - 03/2010)|
|4.||Antonescu, Cristina R: 8 articles (06/2013 - 08/2003)|
|5.||Mechtersheimer, Gunhild: 7 articles (11/2014 - 06/2002)|
|6.||Coindre, Jean-Michel: 6 articles (11/2015 - 09/2003)|
|7.||Pedeutour, Florence: 6 articles (11/2015 - 07/2004)|
|8.||Pilotti, S: 6 articles (10/2014 - 09/2000)|
|9.||Demetri, George D: 6 articles (09/2014 - 09/2002)|
|10.||Kurokawa, Riki: 6 articles (01/2014 - 07/2008)|
|1.||trabectedin (ecteinascidin 743)IBA
07/01/2014 - "The extraction recovery was >81% and the lower limit of quantification 0.025 ng/ml. The method was successfully applied to study trabectedin pharmacokinetics in a patient with a liposarcoma who received 1.3 mg/m² as a 24 h continuous i.v. infusion."
01/01/2015 - "Myxoid (round cell) liposarcomas appear to be sensitive to trabectedin, which is currently under U.S. "
03/15/2010 - "In conclusion, trabectedin has dual effects in liposarcoma: in addition to direct growth inhibition, it affects the tumor microenvironment by reducing the production of key inflammatory mediators."
06/01/2008 - "In myxoid and round-cell liposarcomas trabectedin seems exceptionally active. "
03/01/2012 - "To evaluate neoadjuvant trabectedin (1.5 mg/m(2) 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML) previously untreated with chemotherapy or radiation. "
01/01/2014 - "High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma."
07/01/1999 - "We report a case of retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide. "
07/01/1999 - "[A case of advanced retroperitoneal dedifferentiated liposarcoma treated effectively with high-dose ifosfamide]."
01/01/2005 - "Most other high-grade (grading >I), so-called 'adult type', soft tissue sarcomas such as fibrosarcoma, liposarcoma, pleomorphic and synovial sarcomas are treated with an anthracycline-based regimen with or without ifosfamide as front-line therapy. "
08/01/2011 - "[A case of huge omental-origin liposarcoma controlled by a combination of ifosfamide and adriamycin]."
|3.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/01/2008 - "This study was performed to identify gene expression changes in liposarcoma after doxorubicin treatment. "
01/01/2014 - "Moreover, CDK11 knockdown enhances the cytotoxic effect of doxorubicin to inhibit cell growth in liposarcoma cells. "
03/01/2010 - "Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres."
01/01/2008 - "Doxorubicin is considered one of the most potent established chemotherapeutics in the treatment of liposarcoma; however, the response rates usually below 30%, are still disappointing. "
01/01/2008 - "Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures."
07/01/1995 - "Traditional fluorescence in situ hybridization, and recently, comparative genomic hybridization have uncovered the chromosomal composition of these rings as well as some associated gene amplifications in well-differentiated liposarcoma and dermatofibrosarcoma protuberans."
06/01/2008 - "Notably, the MAD2 overexpression was frequently detected in TA sarcomas with atypical or high-grade morphology, such as round cell liposarcoma and fibrosarcomatous dermatofibrosarcoma protuberans. "
01/01/1998 - "Regarding the last feature these cytogenetic findings resemble those found in low grade parosteal osteosarcomas and other mesenchymal lesions of borderline behavior or low malignancy grade (for example dermatofibrosarcoma protuberans, low grade liposarcoma)."
05/01/1999 - "The analysis included 251 living sarcoma cases (48 dermatofibrosarcoma protuberans, 32 malignant fibrohistiocytic sarcoma, 67 leiomyosarcoma, 53 liposarcoma, and 51 skeletal sarcoma) and 1908 living controls. "
08/01/1992 - "Ring chromosomes have been described as characteristic for two other low-grade malignant mesenchymal neoplasms, well-differentiated liposarcoma and dermatofibrosarcoma protuberans. "
03/01/2014 - "In addition to these compounds there is evidence of efficacy of new drugs such as taxanes in angiosarcoma, gemcitabine+taxanes combination in leiomyosarcomas, trabectedin in leiomyosarcomas and liposarcomas with an extremely high activity in myxoid liposarcoma. "
06/01/2014 - "Examples of more specific treatment options include taxanes in angiosarcoma, and trabectedin in leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma. "
06/01/2014 - "Since peculiar chemosensitivity towards alternative drugs was described for different metastatic subtypes in second or further lines, the modern concept of 'histology-driven chemotherapy' has been accepted and employed: gemicitabine ± dacarbazine, trabectedin and taxanes used respectively in patients with leiomyosarcoma, solitary fibrous tumor, myxoid/round cell liposarcoma, angiosarcoma. "
02/01/2010 - "Apart from Ewing's sarcoma family tumor and rhabdomyosarcoma, there is increasing specialization of chemotherapy according to histological subtype, such as the use of taxanes for angiosarcoma, gemcitabine and docetaxel for leiomyosarcoma, and trabectedin for leiomyosarcoma and liposarcoma, especially the myxoid/round cell variant. "
09/01/2012 - "In addition to doxorubicin and ifosfamide, therefore, there is evidence of efficacy of gemcitabine in leiomyosarcomas; trabectedin in leiomyosarcomas and liposarcomas, with an exceedingly high activity in myxoid liposarcoma; taxanes and gemcitabine in angiosarcoma. "
|6.||zoledronic acid (zoledronate)FDA Link
05/01/2008 - "This is the first study demonstrating the utility of PPAR-gamma immunohistochemistry in the diagnosis of dedifferentiated liposarcoma in tissue sections. "
10/01/2007 - "Taken together, this study provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and establishes that PPARgamma inactivation is required for liposarcoma development."
05/01/2008 - "Although not completely specific, the presence of PPAR-gamma staining, in combination with histologic findings and other markers, can aid in the diagnosis of dedifferentiated liposarcoma, particularly on small biopsies that may not sample the well-differentiated component."
10/01/2007 - "Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development."
05/11/2000 - "We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high levels of the adipocyte regulatory protein PPARgamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPARgamma expression. "
01/01/2013 - "In this study, we demonstrated array effects in microRNA arrays using data from a liposarcoma study. "
01/01/2013 - "We collected microRNA expression profiles for human tissue samples from a liposarcoma study using the Agilent microRNA arrays. "
01/01/2013 - "An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study."
04/01/2012 - "The aim of this study was to elucidate the paracrine impact of liposarcoma cells on pre-adipocytes, their adipogenic differentiation process and miRNA expression profile. "
04/01/2012 - "In this study, we identifed miRNAs associated with the differentiation status of liposarcoma to gain insight into the basis for its progression. "
|9.||troglitazone (Rezulin)FDA Link
10/20/2003 - "One study has shown clinical activity of troglitazone treatment in liposarcoma patients. "
10/01/2002 - "Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma."
03/30/1999 - "We report here the results of three patients with intermediate to high-grade liposarcomas in whom troglitazone administration induced histologic and biochemical differentiation in vivo. "
10/01/2002 - "The biochemical changes occurring in the 3T3 F442A cell line and well-differentiated liposarcoma following induction of adipocyte differentiation with the thiazolidinedione troglitazone were measured using high-resolution magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy. "
03/30/1999 - "We have conducted a clinical trial for treatment of patients with advanced liposarcoma by using the peroxisome proliferator-activated receptor-gamma ligand troglitazone, in which extensive correlative laboratory studies of tumor differentiation were performed. "
|10.||DNA (Deoxyribonucleic Acid)IBA
11/10/1996 - "Cellular DNA content analysis has helped to estimate the biological behavior of a gastrointestinal stromal tumour originating from the stomach and a retroperitoneal dedifferentiated type of a well differentiated liposarcoma. "
05/01/2005 - "Only eight of the 17 patients with myxoid/round cell liposarcomas showed changes in DNA copy number (mean 3.4 imbalances). "
01/01/1998 - "Here we describe the use of transfection experiments utilizing DNA from a human pleomorphic liposarcoma to identify a novel gene, designated lip which maps to chromosome 19.Results. "
08/16/1994 - "In the case of the liposarcoma, transactivation by the FUS-CHOP protein occurs because the FUS transcriptional activation domain is added to the DNA-binding CHOP protein normally lacking such activity. "
09/01/1991 - "In addition, following transfection of DNA from a liposarcoma, we identified an activated gene that failed to hybridize to probes prepared from 10 known human oncogenes (K-ras, H-ras, N-ras, ret, met, trk, mas, dbl, raf and hst) that have previously been detected in DNA transfection experiments. "
|1.||Drug Therapy (Chemotherapy)
09/01/2014 - "Retroperitoneal dedifferentiated liposarcoma is associated with a poor prognosis, and the efficacy of chemotherapy in such cases is controversial. "
11/01/2012 - "We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection. "
03/01/2010 - "III. Chemotherapy of liposarcoma--the current status of chemotherapy and new findings in clinical trials of novel drugs]."
01/01/2014 - "Targeting the PI3K/AKT/pathway with small molecule inhibitors in combination with chemotherapy could be exploited as a novel strategy in the treatment of liposarcoma. "
01/01/2014 - "Liposarcoma cell lines were used to determine the effects of PI3K targeted drug treatment with or without chemotherapy. "
01/01/2007 - "The aim of the study was to investigate the clinical and morphological effects of radiotherapy in the treatment of myxoid/round cell liposarcoma (MLS/RCLS). "
01/01/2000 - "Studies on liposarcoma at other sites indicate that addition of radiotherapy to surgery may result in longer local recurrence-free survival, though without improvement of overall survival."
08/01/2015 - "Dedifferentiated liposarcomas (DDLPS) are highly resistant to conventional chemo- and radiotherapies, with surgical resection remaining the classic treatment strategy; therefore, there is a pressing need for novel anti-DDLPS-targeted chemotherapeutics. "
12/01/2011 - "The relapse and resistance to chemo- and radiotherapy are main problems in the treatment of human liposarcoma. "
01/01/2010 - "We describe the complete resection of a giant, well-differentiated mediastinal liposarcoma extending retropharynx to envelop the aortic arch, trachea and esophagus following preoperative radiotherapy."
02/01/1999 - "We reported a 36-year-old woman with metastatic liposarcoma originating in the retroperitoneum, which responded well to adjuvant chemotherapy. "
04/01/1993 - "Currently, no evidence exists that adjuvant chemotherapy is indicated for patients with liposarcoma, although numerous studies are being done to investigate its use. "
08/01/2012 - "The patient received 4 series of adjuvant chemotherapy after the postoperative diagnosis of dedifferentiated liposarcoma. "
03/01/2015 - "Primary mesenteric liposarcoma is extremely rare, and the treatment strategy is surgical resection with a wide free margin, often followed by radiation and adjuvant chemotherapy if distant metastasis is not detected. "
11/01/2006 - "The treatment strategy for mesenteric liposarcoma is, if no distant metastases are detected, surgical resection with a wide surgical margin, often followed by radiation and/or adjuvant chemotherapy for high-risk patients. "
|4.||Combination Drug Therapy (Combination Chemotherapy)
01/01/1982 - "Partial remission (greater than 50%) was obtained in one patient with a liposarcoma who had also responded to prior combination chemotherapy. "
06/01/2001 - "He had been diagnosed 13 years before as having a liposarcoma, at which point he was treated with combination chemotherapy, which included anthracycline. "
02/01/1999 - "[A case of metastatic liposarcoma originating in the retroperitoneum successfully treated with combination chemotherapy]."
01/01/1983 - "This combination chemotherapy is worth trying if a patient has inoperable liposarcoma. "
02/01/1999 - "Although the role of chemotherapy for liposarcoma has not been well defined and little data support its use in an adjuvant setting, this combination chemotherapy seemed to be effective for advanced liposarcoma."
|5.||Heterologous Transplantation (Xenotransplantation)
03/10/2015 - "Here, we show that reducing SPIN1 levels strongly impairs proliferation and increases apoptosis of liposarcoma cells in vitro and in xenograft mouse models. "
01/01/2015 - "Stable AXL knockdown not only decreased migratory and invasive characteristics of DDLPS and PLS cells in vitro but also significantly diminished tumorigenicity of two dedifferentiated liposarcoma xenograft models in vivo. "
05/01/2014 - "The stability of the angiogenic phenotype was examined using an established human liposarcoma xenograft model. "
04/01/2013 - "These human xenograft models may facilitate liposarcoma research and accelerate the generation of readily translatable preclinical data that could ultimately influence patient care."
04/01/2013 - "Because very few in vivo and in vitro models can reproducibly recapitulate the human disease, we generated several xenograft models from surgically resected human dedifferentiated liposarcoma. "